The DOI matches its Crossref record; 167 of the 167 references it cites were found in a registry or an index.
The Synaptic Vesicle Glycoprotein 2: Structure, Function, and Disease Relevance
Open accessAbstract
The synaptic vesicle glycoprotein 2 (SV2) family is comprised of three paralogues: SV2A, SV2B, and SV2C. In vertebrates, SV2s are 12-transmembrane proteins present on every secretory vesicle, including synaptic vesicles, and are critical to neurotransmission. Structural and functional studies suggest that SV2 proteins may play several roles to promote proper vesicular function. Among these roles are their potential to stabilize the transmitter content of vesicles, to maintain and orient the releasable pool of vesicles, and to regulate vesicular calcium sensitivity to ensure efficient, coordinated release of the transmitter. The SV2 family is highly relevant to human health in a number of ways. First, SV2A plays a role in neuronal excitability and as such is the specific target for the antiepileptic drug levetiracetam. SV2 proteins also act as the target by which potent neurotoxins, particularly botulinum, gain access to neurons and exert their toxicity. Both SV2B and SV2C are increasingly implicated in diseases such as Alzheimer's disease and Parkinson's disease. Interestingly, despite decades of intensive research, their exact function remains elusive. Thus, SV2 proteins are intriguing in their potentially diverse roles within the presynaptic terminal, and several recent developments have enhanced our understanding and appreciation of the protein family. Here, we review the structure and function of SV2 proteins as well as their relevance to disease and therapeutic development.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“SV2A is a core presynaptic regulator that coordinates vesicle priming, calcium dependent release, and neurotransmitter loading to ensure reliable synaptic transmission [184,185,186].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [184]
In the citing paper
“Through these convergent actions, SV2A functions as a molecular scaffold that stabilizes presynaptic terminals while postsynaptic strengthening consolidates [175,184,198].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [184]
In the citing paper
“evidence from structural and functional studies suggests SV2 proteins play multiple roles in the “life cycle” of a synaptic vesicle to promote proper vesicular function”
From Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression (2025) · cites this paper as [46]
Citations
Cites
Finishing the euchromatic sequence of the human genome
International Human Genome Sequencing Consortium (2004) · Nature · doi:10.1038/nature03001 · Cited by 4,971
Zerbino, D. R., Achuthan, P., Akanni, W., Amode, M. R., Barrell, D., Bhai, J., Billis, K., Cummins, C., Gall, A., Girón, C. G., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1098 · Cited by 2,605
Südhof, T. C. (2004) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.26.041002.131412 · Cited by 2,547
Molecular anatomy of a trafficking organelle
Takamori, S., Holt, M., Stenius, K., Lemke, E. A., Grønborg, M., Riedel, D., Urlaub, H., Schenck, S., Brügger, B., Ringler, P., et al. (2006) · Cell · doi:10.1016/j.cell.2006.10.030 · Cited by 2,373
Pao, S. S., Paulsen, I. T., & Saier, M. H. (1998) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.62.1.1-34.1998 · Cited by 2,297
The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam
Lynch, B. A., Lambeng, N., Nocka, K., Kensel-Hammes, P., Bajjalieh, S. M., Matagne, A., & Fuks, B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308208101 · Cited by 1,610
Protter: interactive protein feature visualization and integration with experimental proteomic data
Omasits, U., Ahrens, C. H., Müller, S., & Wollscheid, B. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt607 · Cited by 1,347
Neurotransmitter Release: The Last Millisecond in the Life of a Synaptic Vesicle
Südhof, T. C. (2013) · Neuron · doi:10.1016/j.neuron.2013.10.022 · Cited by 1,197
Reduction of Hippocampal Hyperactivity Improves Cognition in Amnestic Mild Cognitive Impairment
Bakker, A., Krauss, G. L., Albert, M. S., Speck, C. L., Jones, L. R., Stark, C. E., Yassa, M. A., Bassett, S. S., Shelton, A. L., & Gallagher, M. (2012) · Neuron · doi:10.1016/j.neuron.2012.03.023 · Cited by 908
SV2 Is the Protein Receptor for Botulinum Neurotoxin A
Dong, M., Yeh, F., Tepp, W. H., Dean, C., Johnson, E. A., Janz, R., & Chapman, E. R. (2006) · Science · doi:10.1126/science.1123654 · Cited by 770
Research works printed but not linked: 2
- Damaj M. I., 1997, J. Pharmacol. Exp. Ther., 282, 410
- Harrod S. B., 2001, J. Pharmacol. Exp. Ther., 298, 172
Cited by
Levetiracetam Mechanisms of Action: From Molecules to Systems
Contreras-García, I. J., Cárdenas-Rodríguez, N., Romo-Mancillas, A., Bandala, C., Zamudio, S. R., Gómez-Manzo, S., Hernández-Ochoa, B., Mendoza-Torreblanca, J. G., & Pichardo-Macías, L. A. (2022) · Pharmaceuticals · doi:10.3390/ph15040475 · Cited by 131
“[8,91,119]; then, LEV would act as improver of synaptic vesicle exocytosis.”
BackgroundEmerging roles of N-linked glycosylation in brain physiology and disorders
Conroy, L. R., Hawkinson, T. R., Young, L. E. A., Gentry, M. S., & Sun, R. C. (2021) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2021.09.006 · Cited by 109
Kamondi, A., Grigg-Damberger, M. M., Löscher, W., Tanila, H., & Horvath, A. A. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-00932-4 · Cited by 127
“SV2B has also been implicated in the pathophysiology of AD 169 .”
Emerging Roles of the Human Solute Carrier 22 Family
Yee, S. W., & Giacomini, K. M. (2021) · Drug Metabolism and Disposition · doi:10.1124/dmd.121.000702 · Cited by 84
Bortolami, M., Rocco, D., Messore, A., Santo, R. D., Costi, R., Madia, V. N., Scipione, L., & Pandolfi, F. (2021) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2021.1874344 · Cited by 73
Metadata
- Authors
- Stout, K. A., Dunn, A. R., Hoffman, C., & Miller, G. W.
- Affiliations
- Northwestern University (US)
- Jackson Laboratory (US)
- Emory University (US)
- Columbia University (US)
- Corresponding author
- Stout, Kristen A.
- Miller, Gary W.
- Venue
- ACS Chemical Neuroscience
- Publisher
- American Chemical Society (ACS)
- Published
- 2019-08-08
- Volume
- 10
- Issue
- 9
- Pages
- 3927-3938
- ISSN
- 1948-7193 (ISSN-L)
- PMC
- PMC11562936
- OpenAlex
- W2967602434
- Cited by
- 112
- References
- 167
- Citations by year
- 2026: 16 · 2025: 21 · 2024: 23 · 2023: 19 · 2022: 13 · 2021: 13 · 2020: 5 · 2019: 1
- FWCI
- 0.93
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- Locations
- ACS Chemical Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- The Mouseion at the JAXlibrary (Jackson Laboratory) (submittedVersion)
- Funders
- U.S. Department of Health and Human Services (ES012870, ES023839, NS089242, AG058396, DA037652)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular transport and secretion
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Clinical Neurology › Botulinum Toxin and Related Neurological Disorders
- Keywords
- SV2A, SV2B, SV2C, neurotransmitter release, presynaptic terminals, secretory vesicles, levetiracetam, botulinum toxin, Alzheimer's disease, Parkinson's disease, neuronal excitability, paralogs
- MeSH terms
- Animals, Humans, Membrane Glycoproteins, Nerve Tissue Proteins, Nervous System Diseases, Synaptic Vesicles, Protein Transport
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Synaptic Vesicle Glycoprotein 2: Structure, Function, and Disease Relevance. https://app.cochat.ai/papers/10.1021/acschemneuro.9b00351
- The paper
- Stout, K. A., Dunn, A. R., Hoffman, C., & Miller, G. W. (2019). The Synaptic Vesicle Glycoprotein 2: Structure, Function, and Disease Relevance. ACS Chemical Neuroscience. https://doi.org/10.1021/acschemneuro.9b00351
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.